Invesaro

Stocks Health care CNTB

NASDAQ · Health care

Connect Biopharma Holdings Ltd (CNTB)

Connect Biopharma Holdings Ltd brought in $3M of revenue over the twelve months to June 30, 2026. It posted a net loss of $69M. In fiscal 2025 capital spending exceeded operating cash flow by $51.6M. At June 30, 2026 it held $27M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.

Price
$1.08
-1.82% on the day · September 25, 2026
52-week range $1.06 to $3.82
Market cap
$68M
Revenue (last 12 months)
$3M
Net margin
-2,336.3%

What Connect Biopharma Holdings Ltd does

Connect Biopharma Holdings Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CNTB.

Revenue and profit by year

Revenue
FY23: $0 $0 FY23FY24: $26M $26M FY24FY25: $64K $64K FY25
Net income
FY21: -$202.3M -$202.3M FY21FY22: -$118.1M -$118.1M FY22FY23: -$62.1M -$62.1M FY23FY24: -$15.6M -$15.6M FY24FY25: -$55.5M -$55.5M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$64K-$58.1M-$55.5M-$1.00-$51.6M
2024$26M-$22.5M-$15.6M-$0.28-$24.4M
2023$0-$69.1M-$62.1M-$1.13-$47.8M
2022n/a-$119.3M-$118.1M-$2.25-$105.9M
2021n/a-$98.1M-$202.3M-$4.06-$88.2M

Latest SEC filings

What Connect Biopharma Holdings Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 15, 2026
  2. August 14, 2026
  3. August 14, 2026
  4. August 12, 2026
    Quarterly report 10-Q · period to June 30, 2026
  5. August 12, 2026
  6. May 15, 2026
  7. May 15, 2026
  8. May 12, 2026
    Quarterly report 10-Q · period to March 31, 2026
  9. May 12, 2026
  10. April 23, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 1, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about CNTB

What does Connect Biopharma Holdings Ltd do?

Connect Biopharma Holdings Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CNTB.

Is Connect Biopharma Holdings Ltd profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $69M on revenue of $3M.

How much revenue does Connect Biopharma Holdings Ltd make?

Over the twelve months to June 30, 2026 Connect Biopharma Holdings Ltd reported revenue of $3M.

When did Connect Biopharma Holdings Ltd last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 15, 2026.

Similar companies

Follow CNTB

Get an email when Connect Biopharma Holdings Ltd files with the SEC: results, executive changes, material agreements and annual reports.

Follow CNTB: get an email when it files

Where the numbers come from

Financial figures are the values Connect Biopharma Holdings Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.